Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
<iframe src="https://statesidedaily.com/embed/cluster/23c88cfb517440c24c197bc86a2ae6faec78cdef" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future"></iframe>
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
